Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1,800,000 Profiles
More than 3,500 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Louis Lasagna

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.8 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Geographic Areas

United States

Organizations

Procedures

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kaptchuk Ted J; Kelley John M; Deykin Aaron; Wayne Peter M; Lasagna Louis C; Epstein Ingrid O; Kirsch Irving; Wechsler Michael E
Do "placebo responders" exist?
Conboy Lisa A; Wasserman Rachel H; Jacobson Eric E; Davis Roger B; Legedza Anna T R; Park Min; Rivers Andrea L; Morey Elizabeth B; Nam Bong Hyun; Lasagna Louis; Kirsch Irving; Lembo Anthony J; Kaptchuk Ted J; Kerr Catherine E
Investigating placebo effects in irritable bowel syndrome: a novel research design.
Lasagna Louis
Statistical uncertainty.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Louis Lasagna (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Kaptchuk Ted J; Kelley John M; Deykin Aaron; Wayne Peter M; Lasagna Louis C; Epstein Ingrid O; Kirsch Irving; Wechsler Michael E
Do "placebo responders" exist?
Contemporary clinical trials 2008;29(4):587-95.
2006: Conboy Lisa A; Wasserman Rachel H; Jacobson Eric E; Davis Roger B; Legedza Anna T R; Park Min; Rivers Andrea L; Morey Elizabeth B; Nam Bong Hyun; Lasagna Louis; Kirsch Irving; Lembo Anthony J; Kaptchuk Ted J; Kerr Catherine E
Investigating placebo effects in irritable bowel syndrome: a novel research design.
Contemporary clinical trials 2006;27(2):123-34.
2002: Lasagna Louis
Statistical uncertainty.
Clinical therapeutics 2002;24(4):471-2.
2000: Levine R J; Lasagna L
Demystifying central review boards: current options and future directions.
IRB 2000;22(6):1-9.
2000: Lasagna L
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
JAMA : the journal of the American Medical Association 2000;283(15):2013-4.
2000: Lasagna L
The mind and morality of the doctor. II. The physician and the macrocosm. 1965.
The Yale journal of biology and medicine 2000;73(1-6):389-400; discussion 400-2.
1998: Lasagna L; Kaitin K I
Issues facing the new FDA commissioner.
Science (New York, N.Y.) 1998;282(5392):1263.
1998: Lasagna L
Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine.
Journal of clinical pharmacology 1998;38(7):570-1.
1998: Byrd D M; Allen D O; Beamer R L; Besch H R; Bylund D B; Doull J; Fleming W W; Fries A; Guengerich F P; Hornbrook R; Lasagna L; Lum B K; Michaelis E K; Morgan E T; Poland A; Rozman K K; Smith J B; Swanson H I; Waddell W; Wilson J D
The dose-response model for dioxin.
Risk analysis : an official publication of the Society for Risk Analysis 1998;18(1):1-2.
1998: Lasagna L
Defining our future work.
PharmacoEconomics 1998;14 Suppl 1():143-6.
1998: Lasagna L
Balancing risks versus benefits in drug therapy decisions.
Clinical therapeutics 1998;20 Suppl C():C72-9.
1997: Manocchia M; Lasagna L
Issues in pharmaceutical lotteries: the case of interferon beta-1b.
Clinical pharmacology and therapeutics 1997;62(3):241-7.
1997: Lasagna L
Recent trends in drug development.
Publication - American Institute of the History of Pharmacy 1997;16():217-22.
1996: Lasagna L; Frei E
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference.
American journal of clinical oncology 1996;19(4):325-9.
1996: Lasagna L
Update to "Over-the-counter hypnotics and chronic insomnia in the elderly" (guest editorial, J Clin Psychopharmacol 1995;15:383-6)
Journal of clinical psychopharmacology 1996;16(2):191.
1996: Lasagna L
Defining our future work.
PharmacoEconomics 1996;10 Suppl 2():139-41.
1995: Lasagna L
Over-the-counter hypnotics and chronic insomnia in the elderly.
Journal of clinical psychopharmacology 1995;15(6):383-6.
1995: Brown J S; Bienz-Tadmor B; Lasagna L
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991.
Clinical pharmacology and therapeutics 1995;58(3):243-56.
1995: Bakke O M; Manocchia M; de Abajo F; Kaitin K I; Lasagna L
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.
Clinical pharmacology and therapeutics 1995;58(1):108-17.
1995: Lasagna L
The Helsinki Declaration: timeless guide or irrelevant anachronism?
Journal of clinical psychopharmacology 1995;15(2):96-8.
1995: DiMasi J A; Hansen R W; Grabowski H G; Lasagna L
Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
PharmacoEconomics 1995;7(2):152-69.
1994: Lasagna L; Shader R I
A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics.
Journal of clinical pharmacology 1994;34(8):812-5.
1994: DiMasi J A; Seibring M A; Lasagna L
New drug development in the United States from 1963 to 1992.
Clinical pharmacology and therapeutics 1994;55(6):609-22.
1994: Lasagna L
Over-the-counter niacin.
JAMA : the journal of the American Medical Association 1994;271(9):709-10.
1994: Kaitin K I; Manocchia M; Seibring M; Lasagna L
The new drug approvals of 1990, 1991, and 1992: trends in drug development.
Journal of clinical pharmacology 1994;34(2):120-7.
1993: Kaitin K I; Bryant N R; Lasagna L
The role of the research-based pharmaceutical industry in medical progress in the United States.
Journal of clinical pharmacology 1993;33(5):412-7.
1993: Lasagna L
Macrocyclic molecules and their pharmacological applications.
European journal of rheumatology and inflammation 1993;12(4):3-5.
1992: Weintraub M; Sundaresan P R; Madan M; Schuster B; Balder A; Lasagna L; Cox C
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
Clinical pharmacology and therapeutics 1992;51(5):586-94.
1992: Bienz-Tadmor B; Dicerbo P A; Tadmor G; Lasagna L
Biopharmaceuticals and conventional drugs: clinical success rates.
Bio/technology (Nature Publishing Company) 1992;10(5):521-5.
1992: Orzack L H; Kaitin K I; Lasagna L
Pharmaceutical regulation in the European Community: barriers to single market integration.
Journal of health politics, policy and law 1992;17(4):847-68.
1991: DiMasi J A; Bryant N R; Lasagna L
New drug development in the United States from 1963 to 1990.
Clinical pharmacology and therapeutics 1991;50(5 Pt 1):471-86.
1991: DiMasi J A; Hansen R W; Grabowski H G; Lasagna L
Cost of innovation in the pharmaceutical industry.
Journal of health economics 1991;10(2):107-42.
1991: DiMasi J A; Kaitin K I; Fernandez-Carol C; Lasagna L
New indications for already-approved drugs: an analysis of regulatory review times.
Journal of clinical pharmacology 1991;31(3):205-15.
1991: Kaitin K I; DiCerbo P A; Lasagna L
The new drug approvals of 1987, 1988, and 1989: trends in drug development.
Journal of clinical pharmacology 1991;31(2):116-22.
1991: Lasagna Louis
Mortal decisions: What Kind of Life and Who Lives? Who Dies?
The Sciences 1991;31(1):43-6.
1991: Lasagna L
Advocacy: a new role for cancer patients.
Cancer investigation 1991;9(5):609-10.
1990: Wastila L J; Richard B W; Dicerbo P A; Lasagna L
The Catastrophic Care Act: lessons to be learned.
American pharmacy 1990;NS30(6):22-3.
1990: Lasagna L
Are drug benefits also part of pharmacoepidemiology?
Journal of clinical epidemiology 1990;43(9):849-50.
1989: Richard B W; Ulcickas M; Lasagna L
Approvable letters in the FDA new drug approval process.
Journal of clinical pharmacology 1989;29(8):680-4.
1989: Kaitin K I; Mattison N; Northington F K; Lasagna L
The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987.
Clinical pharmacology and therapeutics 1989;46(2):121-38.
1989: Lasagna L
Congress, the FDA, and new drug development: before and after 1962.
Perspectives in biology and medicine 1989;32(3):322-43.
1988: Lasagna L
Involuntary self-intoxication with triazolam.
Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Université d'Ottawa 1988;13(3):175.
1988: Richard B W; Lasagna L
Anorectic drugs: drug policy making at the state level.
Journal of clinical pharmacology 1988;28(5):396-400.
1988: Mattison N; Trimble A G; Lasagna L
New drug development in the United States, 1963 through 1984.
Clinical pharmacology and therapeutics 1988;43(3):290-301.
1988: Lasagna L
Over-the-counter analgesics: rational developments in the future.
Agents and actions. Supplements 1988;25():69-76.
1987: Lasagna L
Benefit-risk ratio of agonist-antagonist analgesics.
Drug and alcohol dependence 1987;20(4):385-93.
1987: Kaitin K I; Richard B W; Lasagna L
Trends in drug development: the 1985-86 new drug approvals.
Journal of clinical pharmacology 1987;27(8):542-8.
1987: Lasagna L
The Lilly Prize lecture. University of London, December 1986. On assuring pharmacotherapeutic progress in the 21st century.
British journal of clinical pharmacology 1987;23(6):659-65.
1987: Richard B W; Lasagna L
Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
Annals of internal medicine 1987;106(6):886-91.
1987: Spivey R N; Lasagna L; Trimble A G
New indications for already-approved drugs: time trends for the new drug application review phase.
Clinical pharmacology and therapeutics 1987;41(4):368-70.
1987: Lasagna Louis
The role and responsibility of industry in research.
Dolentium Hominum 1987;4(2nd Yr. 1):56-9.
1987: Lasagna L
Ethics and informed consent.
Journal of chronic diseases 1987;40(3):277-8.
1987: Lasagna L
Does the public need protection from itself?
Clinical therapeutics 1987;9(3):240-2.
1987: Lasagna L
The desire to regulate: the wish to discover.
Drugs under experimental and clinical research 1987;13(11):659-64.
1986: Lasagna L
Clinical testing of products prepared by biotechnology.
Regulatory toxicology and pharmacology : RTP 1986;6(4):385-90.
1986: Lasagna L
The economics of generic prescribing: winners and losers.
JAMA : the journal of the American Medical Association 1986;256(18):2566.
1986: Lasagna L
On reducing waste in foreign clinical trials and postregulation experience.
Clinical pharmacology and therapeutics 1986;40(4):369-72.
1986: Lasagna L
Pain and its management.
Hospital practice (Office ed.) 1986;21(10):92C-92K, 92O-92P, 92S passim.
1986: Lasagna L
The placebo effect.
The Journal of allergy and clinical immunology 1986;78(1 Pt 2):161-5.
1986: Lasagna L; Greenblatt D J
More than skin deep: transdermal drug-delivery systems.
The New England journal of medicine 1986;314(25):1638-9.
1986: Cox C; Davis H T; Wardell W M; Calimlim J F; Lasagna L
Graphical analysis of multivariate pain data in analgesic trials.
Controlled clinical trials 1986;7(1):53-64.
1986: Lasagna L
The management of pain.
Drugs 1986;32 Suppl 4():1-7.
1986: Rivera-Calimlim L; Calimlim J F; Liang R; Lasagna L; Diamond G L
Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
The Journal of asthma : official journal of the Association for the Care of Asthma 1986;23(3):113-22.
1985: Wu D Z; Zhang Y Q; Keng P; Sutherland R M; Lasagna L
The interaction between bleomycin and radiation on cell survival and DNA damage in mammalian cell cultures.
International journal of radiation oncology, biology, physics 1985;11(12):2125-31.
1985: Lasagna L; Calimlim J F
Oral ciramadol in the treatment of postoperative pain.
Clinical pharmacology and therapeutics 1985;38(2):176-82.
1985: Waife S O; Lasagna L
From DNA to NDA--the impact of recombinant DNA technology on new drug development.
Regulatory toxicology and pharmacology : RTP 1985;5(2):212-24.
1985: Lasagna L
Phenylpropanolamine and blood pressure.
JAMA : the journal of the American Medical Association 1985;253(17):2491-3.
1985: Spivey R N; Lasagna L; Trimble A G
New drug applications: how long to gain approval?
Clinical pharmacology and therapeutics 1985;37(4):361-6.
1985: Lasagna L
Clinical pharmacology in the United States: a personal reminiscence.
Annual review of pharmacology and toxicology 1985;25():27-31.
1985: Lasagna L
Analgesics in the 1980s.
Clinical therapeutics 1985;7(2):128-30.
1985: Lasagna L
Is the social use of marijuana dangerous or addicting?
Advances in alcohol & substance abuse 1985;5(1-2):77-81.
1984: Lasagna Louis
The price of prestige.
The Sciences 1984;25(1):58, 60.
1984: Madan M; Mehta G; Weintraub M; Lasagna L; Liang R
Perioperative prophylaxis with cephalosporins.
Clinical pharmacology and therapeutics 1984;36(6):712-5.
1984: Lasagna Louis
A duty to die?
The Sciences 1984;24(4):7-8.
1984: Bakke O M; Wardell W M; Lasagna L
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety.
Clinical pharmacology and therapeutics 1984;35(5):559-67.
1983: Lasagna Louis
The executioner's syringe.
The Sciences 1983;23(5):7-8.
1983: Lasagna L
Generic drugs and the elderly.
Journal of the American Geriatrics Society 1983;31(9):571-2.
1983: Sriwatanakul K; Lasagna L; Cox C
Evaluation of current clinical trial methodology in analgesimetry based on experts' opinions and analysis of several analgesic studies.
Clinical pharmacology and therapeutics 1983;34(3):277-83.
1983: Sriwatanakul K; Kelvie W; Lasagna L; Calimlim J F; Weis O F; Mehta G
Studies with different types of visual analog scales for measurement of pain.
Clinical pharmacology and therapeutics 1983;34(2):234-9.
1983: Lasagna L
The professional-patient dialogue.
The Hastings Center report 1983;13(4):9-11.
1983: Sriwatanakul K; Weis O F; Alloza J L; Kelvie W; Weintraub M; Lasagna L
Analysis of narcotic analgesic usage in the treatment of postoperative pain.
JAMA : the journal of the American Medical Association 1983;250(7):926-9.
1983: May M S; Wardell W M; Lasagna L
New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979.
Clinical pharmacology and therapeutics 1983;33(6):691-700.
1983: Lasagna L
Discovering adverse drug reactions.
JAMA : the journal of the American Medical Association 1983;249(16):2224-5.
1983: Alloza J L; Lasagna L
A comparison of drug product information in four national compendia.
Clinical pharmacology and therapeutics 1983;33(3):269-77.
1983: Weis O F; Sriwatanakul K; Weintraub M; Lasagna L
Reduction of anxiety and postoperative analgesic requirements by audiovisual instruction.
Lancet 1983;1(8314-5):43-4.
1983: Weis O F; Sriwatanakul K; Alloza J L; Weintraub M; Lasagna L
Attitudes of patients, housestaff, and nurses toward postoperative analgesic care.
Anesthesia and analgesia 1983;62(1):70-4.
1983: Lasagna L C; Lindzey G
Marijuana policy and drug mythology.
Society 1983;20(2):67-78.
1982: Lasagna L
Sounding Boards. Historical controls: the practitioner's clinical trials.
The New England journal of medicine 1982;307(21):1339-40.
1982: Lasagna Louis
Murder most foul.
The Sciences 1982;22(6):7-8.
1982: Sriwatanakul K; Kelvie W; Lasagna L
The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials.
Clinical pharmacology and therapeutics 1982;32(2):143-8.
1982: Calimlim J F; Wardell W M; Sriwatanakul K; Lasagna L; Cox C
Analgesic efficacy of parenteral metkephamid acetate in treatment of postoperative pain.
Lancet 1982;1(8286):1374-5.
1982: Lasagna L
Will all new drugs become orphans?
Clinical pharmacology and therapeutics 1982;31(3):285-9.
1982: Lasagna L
Are we an over-medicated society?
The Internist 1982;23(1):6-7.
1982: Lasagna L
Patient package inserts: goals versus achievements.
Drug therapeutics 1982;():181-9.
1982: Lasagna L
The Boston State Hospital case (Rogers v. Okin): a legal, ethical, and medical morass.
Perspectives in biology and medicine 1982;25(3):382-403.
1981: Lasagna Louis
Unwilling patients.
The Sciences 1981;21(8):32.
1981: Weintraub M; Glickstein S; Lasagna L
Estrogen patient package insert: medication acceptance despite negative attitudes.
Clinical pharmacology and therapeutics 1981;30(2):149-53.
1981: Lasagna L
Towards a rapprochement between clinical pharmacology and behavioral pharmacology.
NIDA research monograph 1981;37():21-6.
1981: Lasagna L
Heroin: a medical "me too".
The New England journal of medicine 1981;304(25):1539-40.
1981: Lasagna L
Bias in the elucidation of subjective side-effects.
British journal of clinical pharmacology 1981;11 Suppl 1():111S-113S.
1980: Lasagna L
Regulation and constraint of medical research: rights and human welfare.
The American review of respiratory disease 1980;122(3):361-4.
1980: Lasagna L
The World Health Organization list of "essential drugs.".
Annals of internal medicine 1980;93(2):368-9.
1980: Lasagna L
The halcion story.
Lancet 1980;1(8181):1304-5.
1980: Lasagna L
Analgesic methodology: a brief history and commentary.
Journal of clinical pharmacology 1980;20(5-6 Pt 2):373-6.
1980: Lasagna L
The Halcion story: trial by media.
Lancet 1980;1(8172):815-6.
1980: Francetic I; Lasagna L; Weintraub M; Karch F E
Prescription prices under the New York generic substitution law.
Annals of internal medicine 1980;92(3):419-23.
1980: Lasagna Louis
The powerful cipher.
The Sciences 1980;20(2):31-2.
1980: Lasagna L
[Clinical pharmacology in USA and Western Countries (author's transl)]
Lijec?nic?ki vjesnik 1980;102(3):113-5.
1980: Lasagna L
Post-marketing surveillance.
Triangle; the Sandoz journal of medical science 1980;19(3-4):107-11.
1979: Lasagna L
Toxicological barriers to providing better drugs.
Archives of toxicology 1979;43(1):27-33.
1979: Lasagna Louis
Regulated research.
The Sciences 1979;19(7):30.
1979: Lasagna L
Drugs for pain.
British medical journal 1979;2(6185):333.
1979: Udkow G P; Lasagna L; Weintraub M; Tamoshunas Z
The safety and efficacy of the estrogen patient package insert. A questionnaire study.
JAMA : the journal of the American Medical Association 1979;242(6):536-9.
1979: Weintraub M; Karch F E; Morgan J P; Trabert N; Sorensen A; Becker L A; Lasagna L
Digoxin-prescribing. Mostly good news.
JAMA : the journal of the American Medical Association 1979;242(5):445-8.
1979: Lasagna L
Placebos and controlled trials under attack.
European journal of clinical pharmacology 1979;15(6):373-4.
1979: Lasagna L
Drug Regulation Reform Act.
Psychopharmacology bulletin 1979;15(3):54-6.
1979: Lasagna L C
Generic vs. brand name drugs--defining and enforcing standards.
The Internist 1979;20(4):11, 13.
1979: Lasagna L
Problems in publication of clinical trial methodology.
Clinical pharmacology and therapeutics 1979;25(5 Pt 2):751-3.
1979: Sundaresan P R; Wardell W M; Weintraub M; Lasagna L
Methodology for demonstrating sustained efficacy of hypnotics: a comparative study of triazolam and flurazepam.
Clinical pharmacology and therapeutics 1979;25(4):391-8.
1979: Lasagna L
The diseases and drug needs of the Third World.
Journal of chronic diseases 1979;32(6):413-4.
1979: Lasagna L
Drug concentrations in neuropsychiatry. Introduction: the rational use of plasma drug levels in clinical medicine.
Ciba Foundation symposium 1979;(74):1-12.
1979: Lasagna L
The impact of regulations on the development of psychoactive drugs.
NIDA research monograph 1979;27():29-35.
1978: Wardell W M; Hassar M; Anavekar S N; Lasagna L
The rate of development of new drugs in the United States, 1963 through 1975.
Clinical pharmacology and therapeutics 1978;24(2):133-45.
1978: Lasagna L
The development and regulation of new medications.
Science (New York, N.Y.) 1978;200(4344):871-3.
1978: Lasagna L
Generic substitution: trick or treat?
JAMA : the journal of the American Medical Association 1978;239(18):1888.
1978: Lasagna L
Wanted: a new type of consumer advocate for drugs.
The New England journal of medicine 1978;298(16):906.
1978: Lasagna L
Current status of international drug regulation.
Medical marketing & media 1978;13(2):37-8, 40, 42-5.
1978: Biddle T L; Weintraub M; Lasagna L
Relationship of serum and myocardial digoxin concentration to electrocardiographic estimation of digoxin intoxication.
Journal of clinical pharmacology 1978;18(1):10-5.
1978: Rivera-Calimlim L; Gift T; Nasrallah H A; Wyatt R J; Lasagna L
Correlation between plasma concentrations of chlorpromazine and clinical response.
Communications in psychopharmacology 1978;2(3):215-22.
1978: Wyatt R J; Lasagna L
Low plasma levels of CPZ in patients chronically treated with neuroleptics.
Communications in psychopharmacology 1978;2(2):113-21.
1977: Lasagna L
Prisoner subjects and drug testing.
Federation proceedings 1977;36(10):2349-51.
1977: Lasagna L
The role of benzodiazepines in nonpsychiatric medical practice.
The American journal of psychiatry 1977;134(6):656-8.
1977: Hassar M; Pocelinko R; Weintraub M; Nelson D; Thomas G; Lasagna L
Free-living volunteer's motivations and attitudes toward pharmacologic studies in man.
Clinical pharmacology and therapeutics 1977;21(5):515-9.
1977: Karch F E; Lasagna L
Toward the operational identification of adverse drug reactions.
Clinical pharmacology and therapeutics 1977;21(3):247-54.
1977: Lasagna L
Dose-related sleep disturbances induced by coffee and caffeine.
Clinical pharmacology and therapeutics 1977;21(2):244.
1977: Lasagna L
The adversary system and drug regulation.
Connecticut medicine 1977;41(1):54-5.
1977: Calimlim J F; Wardell W M; Davis H T; Lasagna L; Gillies A J
Analgesic efficacy of an orally administered combination of pentazocine and aspirin. With observations on the use and statistical efficiency of GLOBAL subjective efficacy ratings.
Clinical pharmacology and therapeutics 1977;21(1):34-43.
1976: Lasagna L
Windsor C. Cutting Memorial Lecture. Clinical pharmacology: hard sell or soft?
Hawaii medical journal 1976;35(12):363-6.
1976: Lasagna L
Drug discovery and introduction: regulation and overregulation.
Clinical pharmacology and therapeutics 1976;20(5):507-11.
1976: Lasagna L
Randomized clinical trials.
The New England journal of medicine 1976;295(19):1086-7.
1976: Lasagna L
Propoxyphene napsylate.
Annals of internal medicine 1976;85(5):619-21.
1976: Rivera-Calimlim L; Nasrallah H; Strauss J; Lasagna L
Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.
The American journal of psychiatry 1976;133(6):646-52.
1976: Karch F E; Smith C L; Kerzner B; Mazzullo J M; Weintraub M; Lasagna L
Adverse drug reactions-a matter of opinion.
Clinical pharmacology and therapeutics 1976;19(5 Pt 1):489-92.
1976: Lasagna L
Editorial: How useful are serum digitalis measurements?
The New England journal of medicine 1976;294(16):898-9.
1976: Binns T B; Gross F; Lasagna L; Nicolis F B
International co-operation in drug testing.
British journal of clinical pharmacology 1976;3(2):333-4.
1976: Binns T B; Gross F; Lasagna L; Nicolis F B
International co-operation in drug testing.
European journal of clinical pharmacology 1976;09(5-6):469-70.
1976: Fleckenstein L; Joubert P; Lawrence R; Patsner B; Mazzullo J M; Lasagna L
Oral contraceptive patient information. A questionnaire study of attitudes, knowledge, and preferred information sources.
JAMA : the journal of the American Medical Association 1976;235(13):1331-6.
1976: Binns T B; Gross F; Lasagna L; Nicolis F B
Letter: Medical advisers in the pharmaceutical industry.
Clinical pharmacology and therapeutics 1976;19(2):247-8.
1976: Lasagna L
The problems of drug research and development.
Hospital formulary 1976;11(1):28-9.
1976: Lasagna L
Consensus among experts: the unholy grail.
Perspectives in biology and medicine 1976;19(4):537-48.
1975: Karch F E; Lasagna L
Adverse drug reactions. A critical review.
JAMA : the journal of the American Medical Association 1975;234(12):1236-41.
1975: Lasagna L
Letter: Review of "VD Epidemic".
Annals of internal medicine 1975;83(6):910.
1975: Lasagna L
Herbal pharmacology and medical therapy in the People's Republic of China.
Annals of internal medicine 1975;83(6):887-93.
1975: Joubert P; Lasagna L
Patient package inserts. II. Toward a rational patient package insert.
Clinical pharmacology and therapeutics 1975;18(06):663-9.
1975: Joubert P; Lasagna L
Commentary: Patient package inserts. I. Nature, notions, and needs.
Clinical pharmacology and therapeutics 1975;18(5 Pt 1):507-13.
1975: Lasagna L
Clinical trials of drugs from the viewpoint of the academic investigator (a satire).
Clinical pharmacology and therapeutics 1975;18(5 Pt 2):629-33.
1975: Lasagna L
Letter: Knowledge of drug ingredients.
Annals of internal medicine 1975;83(4):579.
1975: Lasagna L
Commentary. Reflections in a crystal ball.
Clinical pharmacology and therapeutics 1975;18(1):1-8.
1975: Lasagna L
Letters: Rejoinder.
JAMA : the journal of the American Medical Association 1975;232(9):906.
1975: Rivera-Calimlim L; Bosmann H B; Penney D P; Lasagna L
Lysosomal changes in the gut of rats after chronic treatment with phenobarbital.
Biochemical pharmacology 1975;24(11-12):1161-6.
1975: Lasagna L; Wardell W M
Commentary: the FDA, politics, and the public.
JAMA : the journal of the American Medical Association 1975;232(2):141-2.
1975: Lasagna L
Letter: Iron in bread.
JAMA : the journal of the American Medical Association 1975;231(10):1027.
1975: Joubert P; Rivera-Calimlim L; Lasagna L
Commentary. The normal volunteer in clinical investigation: how rigid should selection criteria be?
Clinical pharmacology and therapeutics 1975;17(3):253-7.
1975: Dengler H J; Lasagna L
Report of a workshop on fixed-ratio drug combinations.
European journal of clinical pharmacology 1975;8(2):149-54.
1974: Lasagna L
Letter: Abuse of amphetamines.
The New England journal of medicine 1974;291(15):800.
1974: Mundy G R; Fleckenstein L; Mazzullo J M; Sundaresan P R; Weintraub M; Lasagna L
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap.
JAMA : the journal of the American Medical Association 1974;229(13):1744-8.
1974: Lasagna L
Editorial: Drug costs and drug quality.
Annals of internal medicine 1974;81(2):261-2.
1974: Morgan J P; Wardell W M; Weintraub M; Mazzullo J M; Lasagna L
Clinical trials and tribulations.
Archives of internal medicine 1974;134(2):380-3.
1974: Calimlim J F; Wardell W M; Lasagna L; Gillies A J; Davis H T
Effect of naloxone on the analgesic activity of methadone in a 1:10 oral combination. Time and cost of flirting with the null hypothesis in tests of equivalence.
Clinical pharmacology and therapeutics 1974;15(6):556-64.
1974: Mazzullo J M; Lasagna L; Griner P F
Variations in interpretation of prescription instructions. The need for improved prescribing habits.
JAMA : the journal of the American Medical Association 1974;227(8):929-31.
1974: Lasagna L
Editorial: A plea for the "naturalistic" study of medicines.
European journal of clinical pharmacology 1974;7(3):153-4.
1974: Lasagna L
Minimum acceptable requirements for introduction and marketing of drugs.
Drugs 1974;7(6):409-13.
1973: Rivera-Calimlim L; Castañeda L; Lasagna L
Effects of mode of management on plasma chlorpromazine in psychiatric patients.
Clinical pharmacology and therapeutics 1973;14(6):978-86.
1973: Morgan J P; Wardell W; Lasagna L; Mazzullo J M; Weintraub M; Mudholkar G S; Mietlowski W
Mebutamate as a hypnotic: clinical trial and statistical considerations.
Clinical pharmacology and therapeutics 1973;14(6):1001-12.
1973: Lasagna L
Training in clinical pharmacology.
Clinical pharmacology and therapeutics 1973;14(5):916-7.
1973: Lasagna L
Fault and default.
The New England journal of medicine 1973;289(5):267-8.
1973: Lasagna L
Attitudes toward appetite suppressants. A survey of US physicians.
JAMA : the journal of the American Medical Association 1973;225(1):44-8.
1973: Lasagna Louis
Effecting euthanasia should not be secretive.
National observer (Washington, D.C.) 1973;():13.
1973: Weintraub M; Au W Y; Lasagna L
Compliance as a determinant of serum digoxin concentration.
JAMA : the journal of the American Medical Association 1973;224(4):481-5.
1973: Rivera-Calimlim L; Bosmann H B; Penney D P; Lasagna L
Morphologic and biochemical changes in the gut after chronic treatment with L-dopa.
The Journal of pharmacology and experimental therapeutics 1973;184(2):440-8.
1973: Stetson J B; Robinson K; Wardell W M; Lasagna L
Analgesic activity of oral naproxen in patients with postoperative pain.
Scandinavian journal of rheumatology 1973;():Suppl 2:50-5.
1972: Lasagna L
Hypnotic drugs.
The New England journal of medicine 1972;287(23):1182-4.
1972: Becker M H; Stolley P D; Lasagna L; McEvilla J D; Sloane L M
Correlates of physicians' prescribing behavior.
Inquiry : a journal of medical care organization, provision and financing 1972;9(3):30-42.
1972: Lasagna L
The impact of scientific models on clinical psychopharmacology: a pharmacologist's view.
Seminars in psychiatry 1972;4(3):271-82.
1972: Dujovne C A; Shoeman D; Bianchine J; Lasagna L
Experimental bases for the different hepatotoxicity of erythromycin preparations in man.
The Journal of laboratory and clinical medicine 1972;79(5):832-44.
1972: Stolley P D; Becker M H; McEvilla J D; Lasagna L; Gainor M; Sloane L M
Drug prescribing and use in an American community.
Annals of internal medicine 1972;76(4):537-40.
1972: Lasagna L
Constraints on innovation in drug development and use.
Psychopharmacology bulletin 1972;8(2):43-50.
1972: Lasagna L
Research, regulation and development of new pharmaceuticals: past, present and future. II.
The American journal of the medical sciences 1972;263(2):66-78.
1972: Becker M H; Stolley P D; Lasagna L; McEvilla J D; Sloane L M
Differential education concerning therapeutics and resultant physician prescribing patterns.
Journal of medical education 1972;47(2):118-27.
1972: Stolley P D; Becker M H; Lasagna L; McEvilla J D; Sloane L M
The relationship between physician characteristics and prescribing appropriateness.
Medical care 1972;10(1):17-28.
1972: Lasagna L
Research regulation, and development of new pharmaceuticals: past, present, and future. 1.
The American journal of the medical sciences 1972;263(1):9-18.
1972: Lasagna L
The nature of evidence.
Triangle; the Sandoz journal of medical science 1972;11(4):145-52.
1971: Lasagna L
Influence of age on analgesic pain relief.
JAMA : the journal of the American Medical Association 1971;218(12):1831.
1971: Becker M H; Stolley P D; Lasagna L; McEvilla J D; Sloane L M
Characteristics and attitudes of physicians associated with the prescribing of chloramphenicol.
HSMHA health reports 1971;86(11):993-1003.
1971: Rivera-Calimlim L; Morgan J P; Dujovne C A; Bianchine J R; Lasagna L
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
Biochemical pharmacology 1971;20(11):3051-7.
1971: Lasagna L
FDA 'efficacy' rule: does it work?
Missouri medicine 1971;68(9):712-4.
1971: Lasagna L
Preferences in antibiotic prescribing.
British medical journal 1971;3(5772):474.
1971: Bianchine J R; Calimlim L R; Morgan J P; Dujuvne C A; Lasagna L
Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
Annals of the New York Academy of Sciences 1971;179():126-40.
1971: Pearson J W; Lasagna L; Laird R D
Analgesic activity of oral and intramuscular profadol.
Clinical pharmacology and therapeutics 1971;12(4):683-90.
1971: Rivera-Calimlim L; Dujovne C A; Morgan J P; Lasagna L; Bianchine J R
Absorption and metabolism of L-dopa by the human stomach.
European journal of clinical investigation 1971;1(5):313-20.
1971: Macaraeg P V; Lasagna L; Bianchine J R
A study of hospital staff attitudes concerning the comparative merits of antibiotics.
Clinical pharmacology and therapeutics 1971;12(1):1-12.
1970: Rivera-Calimlim L; Dujovne C A; Morgan J P; Lasagna L; Bianchine J R
L-dopa treatment failure: explanation and correction.
British medical journal 1970;4(5727):93-4.
1970: Dujovne C A; Lavelle G; Weiss P; Bianchine J R; Lasagna L
Toxicity of hepatotoxic drugs on mouse liver tissue culture.
Archives internationales de pharmacodynamie et de thérapie 1970;186(1):84-93.
1970: Lasagna L
One man's odd is another man's even.
Clinical pharmacology and therapeutics 1970;11(3):443-6.
1970: Lasagna L
Ethics of post-hepatitis exercise.
The New England journal of medicine 1970;282(15):875-6.
1970: Bianchine J R; Weiss P; Peaston M J; Hersey R M; Lasagna L
Metabolism of SU-13437--a new hypolipidemic drug in man.
Clinical pharmacology and therapeutics 1970;11(1):97-105.
1970: Lasagna L
Drug evaluation problems in academic and other contexts.
Annals of the New York Academy of Sciences 1970;169(2):503-8.
1970: Weiss P; Dujovne C A; Margolis S; Lasagna L; Bianchine J R
Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients.
Clinical pharmacology and therapeutics 1970;11(1):90-6.
1970: Lasagna L
Challenges in drug evaluation in man.
Annual review of pharmacology 1970;10():413-20.
1969: Stolley P D; Lasagna L
Prescribing patterns of physicians.
Journal of chronic diseases 1969;22(6):395-405.
1969: Lasagna L
The pharmaceutical revolution: its impact on science and society.
Science (New York, N.Y.) 1969;166(910):1227-33.
1969: Lasagna L
The doctor and the dying patient.
Journal of chronic diseases 1969;22(2):65-8.
1969: Dujovne C A; Clark R; Lasagna L
Calcium and CNS symptoms.
The New England journal of medicine 1969;281(5):271-2.
1969: Lasagna L C
The future of clinical pharmacology.
Military medicine 1969;134(7):477-92.
1969: Epstein L C; Lasagna L
Obtaining informed consent. Form or substance.
Archives of internal medicine 1969;123(6):682-8.
1968: Epstein L C; Lasagna L
A comparison of the effects of orally administered barbiturate salts and barbiturate acids on human psychomotor performance.
The Journal of pharmacology and experimental therapeutics 1968;164(2):433-41.
1968: Macaraeg P V; Bianchine J R; Lasagna L
Tolerance to drug-induced writhing in mice.
The Journal of pharmacology and experimental therapeutics 1968;161(1):130-40.
1968: Bianchine J R; Macaraeg P V; Lasagna L; Azarnoff D L; Brunk S F; Hvidberg E F; Owen J A
Drugs as etiologic factors in the Stevens-Johnson syndrome.
The American journal of medicine 1968;44(3):390-405.
1968: Lasagna L
Drugs through the ages.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1968;42(9):198-202.
1968: Macaraeg P V; Lasagna L; Snyderb
Arcus not so senilis.
Annals of internal medicine 1968;68(2):345-54.
1968: Epstein L C; Lasagna L; Connors C K; Rodriguez A
Correlation of dextroamphetamine excretion and drug response in hyperkinetic children.
The Journal of nervous and mental disease 1968;146(2):136-46.
1968: Lasagna L
Some ethical problems in clinical investigation.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1968;42(1):2-5.
1967: Lasagna L
The clinical pharmacologist as a servant of society.
Canadian Medical Association journal 1967;97(3):109-13.
1967: Schelling J L; Lasagna L
A study of cross-tolerance to circulatory effects of organic nitrates.
Clinical pharmacology and therapeutics 1967;8(2):256-60.
1967: Lasagna L
The pharmacological basis for the effective use of hypnotics.
Pharmacology for physicians 1967;1(2):1-4.
1967: Eade N R; Lasagna L
A comparison of acetophenetidin and acetaminophen. II. Subjective effects in healthy volunteers.
The Journal of pharmacology and experimental therapeutics 1967;155(2):301-8.
1967: Lasagna L; Davis M; Pearson J W
A comparison of acetophenetidin and acetaminophen. I. Analgesic effects in postpartum patients.
The Journal of pharmacology and experimental therapeutics 1967;155(2):296-300.
1967: Sjöqvist F; Lasagna L
The hypnotic efficacy of doxylamine.
Clinical pharmacology and therapeutics 1967;8(1):48-54.
1966: Lasagna L
Is narcotic addiction a chronic disease?
Journal of chronic diseases 1966;19(9):949-51.
1966: Prescott L F; Buhs R P; Beattie J O; Speth O C; Trenner N R; Lasagna L
Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients.
Circulation 1966;34(2):308-21.
1966: Lasagna L
Statistics: vital and lively.
Journal of chronic diseases 1966;19(8):815-8.
1966: Lacher J; Lasagna L
Phenformin and lactic acidosis.
Clinical pharmacology and therapeutics 1966;7(4):477-81.
1966: Lasagna L; Werner G
Conjoint clinic on pain and analgesia.
Journal of chronic diseases 1966;19(6):695-709.
1966: Holland J R; Hosley H; Scharlau C; Carbone P P; Frei E; Brindley C O; Hall T C; Shnider B I; Gold G L; Lasagna L; Owens A H; Miller S P
A controlled trial of urethane treatment in multiple myeloma.
Blood 1966;27(3):328-42.
1965: Lasagna L
The quantification of desired and undesired effects of reproductive controls; some principles and problems.
Journal of chronic diseases 1965;18(11):1173-9.
1965: Lasagna L
Drug interaction in the field of analgesic drugs.
Proceedings of the Royal Society of Medicine 1965;58(11 Part 2):978-83.
1965: Clark R L; Lasagna L
How reliable are enteric-coated aspirin preparations?
Clinical pharmacology and therapeutics 1965;6(5):568-74.
1965: LASAGNA L
THE MIND AND MORALITY OF THE DOCTOR. 1. THE PHYSICIAN AND THE MICROCOSM.
The Yale journal of biology and medicine 1965;37():345-60.
1965: LASAGNA L
THE MIND AND MORALITY OF THE DOCTOR. II THE PHYSICIAN AND THE MACROCOSM.
The Yale journal of biology and medicine 1965;37():361-78.
1965: LASAGNA L
DRUG TOXICITY IN MAN: THE PROBLEM AND THE CHALLENGE.
Annals of the New York Academy of Sciences 1965;123():312-5.
1965: SCHELLING J L; TETREAULT L; LASAGNA L; DAVIS M
ABNORMAL TASTE THRESHOLD IN DIABETES.
Lancet 1965;1(7384):508-12.
1965: LASAGNA L; PEARSON J W
ANALGESIC AND PSYCHOTOMIMETIC PROPERTIES OF DEXOXADROL.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1965;118():352-4.
1965: LASAGNA L
THE INVESTIGATOR'S RESPONSIBILITY TO THE PATIENT.
Journal of oral therapeutics and pharmacology 1965;31():468-71.
1964: LASAGNA L
PROBLEMS OF DRUG DEVELOPMENT. THE GOVERNMENT, THE DRUG INDUSTRY, THE UNIVERSITIES, AND THE MEDICAL PROFESSION: PARTNERS OR ENEMIES?
Science (New York, N.Y.) 1964;145():362-7.
1964: LASAGNA L; DEKORNFELD T J; PEARSON J W
THE ANALGESIC EFFICACY AND RESPIRATORY EFFECTS IN MAN OF A BENZOMORPHAN "NARCOTIC ANTAGNOST".
The Journal of pharmacology and experimental therapeutics 1964;144():12-6.
1964: LASAGNA L
THE CLINICAL EVALUATION OF MORPHINE AND ITS SUBSTITUTES AS ANALGESICS.
Pharmacological reviews 1964;16():47-83.
1964: DEKORNFELD T J; PEARSON J W; LASAGNA L
METHOTRIMEPRAZINE IN THE TREATMENT OF LABOR PAIN.
The New England journal of medicine 1964;270():391-4.
1964: LASAGNA L
THE DISEASES DRUGS CAUSE.
Perspectives in biology and medicine 1964;7():457-70.
1963: LASAGNA L
THE INVESTIGATOR'S RESPONSIBILITY TO THE PATIENT.
Journal of chronic diseases 1963;16():955-9.
1963: DEKORNFELD T J; FRAZIER T M; LASAGNA L
Analgesic compounds.
JAMA : the journal of the American Medical Association 1963;183():1051-2.
1963: SEEGAL D; LASAGNA L
The medical center, the patient and the clinician.
Journal of chronic diseases 1963;16():111-3.
1963: OKUN R; LIDDON S C; LASAGNA L
The effects of aggregation, electric shock, and adrenergic blocking drugs on inhibition of the "writhing syndrome".
The Journal of pharmacology and experimental therapeutics 1963;139():107-9.
1963: LASAGNA L
TWENTIETH CENTURY THERAPEUTICS AND RIP VAN WINKLE.
Proceedings of the Rudolf Virchow Medical Society in the City of New York 1963;22():53-64.
1962: DEKORNFELD T J; LASAGNA L; FRAZIER T M
A comparative study of five proprietary analgesic compounds.
JAMA : the journal of the American Medical Association 1962;182():1315-8.
1962: LASAGNA L
The psychophysics of clinical pain.
Lancet 1962;2(7256):572-5.
1962: LAVENSTEIN A F; DACANEY E P; LASAGNA L; VANMETRE T E
Effect of cyproheptadine on asthmatic children. Study of appetite, weight gain, and linear growth.
JAMA : the journal of the American Medical Association 1962;180():912-6.
1962: LASAGNA L
A matter of perspective.
Journal of chronic diseases 1962;15():3-5.
1961: MURPHY J; CASEY W; LASAGNA L
The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects.
The Journal of pharmacology and experimental therapeutics 1961;134():286-90.
1961: LASAGNA L; OWENS A H; SHNIDER B I; GOLD G L
Toxicity after large doses of noscapine.
Cancer chemotherapy reports. Part 1 1961;15():33-4.
1961: LASAGNA L; DEKORNFELD T J
Methotrimeprazine: a new phenothiazine derivative with analgesic properties.
JAMA : the journal of the American Medical Association 1961;178():887-90.
1961: LASAGNA L
Analgesic drugs.
The American journal of the medical sciences 1961;242():620-7.
1961: HOHN R; GROSS G M; GROSS M; LASAGNA L
A doubleblind comparison of placebo and imipramine in the treatment of depressed patients in a state hospital.
Journal of psychiatric research 1961;1():76-91.
1961: LASAGNA L
The role of a division of clinical pharmacology in a university environment.
Postgraduate medicine 1961;29():525-8.
1960: LASAGNA L C
Planning clinical chemotherapy studies.
National Cancer Institute monograph 1960;3():45-9.
1960: ZUBROD C G; IPSEN J; FREI E; LASAGNA L C; LIPSETT M B; GEHAN E; ESCHER G C
Newer techniques and some problems in cooperative group studies.
National Cancer Institute monograph 1960;3():277-92.
1960: DEKORNFELD T J; LASAGNA L
The analgesic potency of piminodine (alvodine).
Journal of chronic diseases 1960;12():252-7.
1960: LASAGNA L
Thalidomide--a new nonbarbiturate sleep--inducing drug.
Journal of chronic diseases 1960;11():627-31.
1960: LASAGNA L
The clinical measurement of pain.
Annals of the New York Academy of Sciences 1960;86():28-37.
1960: DEKORNFELD T J; LASAGNA L
A controlled clinical evaluation of two new analgesics, phenazocine and phenampromid.
Anesthesiology 1960;21():159-62.
1960: HOEHN R; LASAGNA L
Effects of aggregation and temperature on amphetamine toxicity in mice.
Psychopharmacologia 1960;1():210-20.
1960: TORMEY J; LASAGNA L
Relation of thyroid function to acute and chronic effects of amphetamine in the rat.
The Journal of pharmacology and experimental therapeutics 1960;128():201-9.
1959: LASAGNA L
Gripesmanship: a positive approach.
Journal of chronic diseases 1959;10():459-68.
1959: LASAGNA L
A training program in clinical pharmacology.
Postgraduate medicine 1959;26():559-61.
1959: WALKER W G; IBER F L; WALSER M; LASAGNA L
A controlled study of chlorothiazide as a diuretic agent; with a note on untoward reactions in the presence of renal insufficiency.
Journal of chronic diseases 1959;10(1):47-57.
1959: LASAGNA L
[Sedatives and hypnotics.]
Research publications - Association for Research in Nervous and Mental Disease 1959;37():325-33.
1958: LASAGNA L
Extrapolation to studies in man.
Annals of the New York Academy of Sciences 1958;76(3):939-42; discussion 942-9.
1958: LASAGNA L; DE KORNFELD T; SAFAR P
A clinical trial of dextromoramide, (R 875, SKF D-5137).
Journal of chronic diseases 1958;8(6):689-93.
1958: LASAGNA L; DE KORNFELD T J
Analgesic potency of normorphine in patients with postoperative pain.
The Journal of pharmacology and experimental therapeutics 1958;124(3):260-3.
1958: ZIKRIA B A; LASAGNA L; McCANN W P
The relative importance of blood and urinary concentrations of sulfonamide in the treatment of urinary tract infections; a comparison of sulfisoxazole (gantrisin) and sulfamethoxypyridazine (kynex, midicel) in man and rat.
Bulletin of the Johns Hopkins Hospital 1958;103(3):117-24.
1958: LATIES V G; LASAGNA L; GROSS G M; HITCHMAN I L; FLORES J
A controlled trial on chlorpromazine and promazine in the management of delirium tremens.
Quarterly journal of studies on alcohol 1958;19(2):238-43.
1958: LASAGNA L
The drug industry and American medicine.
Journal of chronic diseases 1958;7(5):440-3.
1958: LASAGNA L; LATIES V G; DOHAN J L
Further studies on the pharmacology of placebo administration.
The Journal of clinical investigation 1958;37(4):533-7.
1958: CHANG F F; SAFAR P; LASAGNA L
Narcotic potency and side effects of anileridine and meperidine in man.
The Journal of pharmacology and experimental therapeutics 1958;122(3):370-8.
1958: LASAGNA L; MEIER P
Clinical evaluation of drugs.
Annual review of medicine 1958;9():347-54.
1957: LASAGNA L; MCCANN W P
Effect of tranquilizing drugs on amphetamine toxicity in aggregated mice.
Science (New York, N.Y.) 1957;125(3260):1241-2.
1957: LASAGNA L
The newer hypnotics.
The Medical clinics of North America 1957;41(2):359-68.
1956: LASAGNA L
Across-the-counter hypnotics: boon, hazard, or fraud?
Journal of chronic diseases 1956;4(5):552-4.
1956: VON FELSINGER J M; LASAGNA L; BEECHER H K
The response of normal men to lysergic acid derivatives (di- and monoethyl amides); correlation of personality and drug reactions.
Journal of clinical and experimental psychopathology 1956;17(4):414-28.
1956: IMBODEN J; LASAGNA L
An evaluation of hypnotic drugs in psychiatric patients.
Bulletin of the Johns Hopkins Hospital 1956;99(2):91-100.
1956: LASAGNA L
Introductory statement on a symposium on pain and its relief.
Journal of chronic diseases 1956;4(1):1-3.
1956: LASAGNA L
Drug effects as modified by aging.
Journal of chronic diseases 1956;3(6):567-74.
1956: WAGNER H N; BENNETT I L; LASAGNA L; CLUFF L E; ROSENTHAL M B; MIRICK G S
The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin.
Bulletin of the Johns Hopkins Hospital 1956;98(3):197-215.
1956: LASAGNA L
A study of hypnotic drugs in patients with chronic diseases; comparative efficacy of placebo; methyprylon (noludar) meprobmate (miltown, equanil) pentobarbial; phenobarbital; secobarbital.
Journal of chronic diseases 1956;3(2):122-33.
1956: LASAGNA L
Drug effects as modified by aging.
Research publications - Association for Research in Nervous and Mental Disease 1956;35():83-94.
1955: LASAGNA L
The controlled clinical trial: theory and practice.
Journal of chronic diseases 1955;1(4):353-67.
1955: VON FELSINGER J M; LASAGNA L; BEECHER H K
Drug-induced mood changes in man. II. Personality and reactions to drugs.
Journal of the American Medical Association 1955;157(13):1113-9.
1955: LASAGNA L; VON FELSINGER J M; BEECHER H K
Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts.
Journal of the American Medical Association 1955;157(12):1006-20.
1955: OWENS A H; MARSHALL E K; BROUN G O; ZUBROD C G; LASAGNA L
A comparative evaluation of the hypnotic potency of chloral hydrate and trichloroethanol. I. Studies at the Johns Hopkins University School of Medicine. II. Studies at the St. Louis University School of Medicine. III. Studies at Harvard Medical School.
Bulletin of the Johns Hopkins Hospital 1955;96(2):71-83.
1954: LASAGNA L; BEECHER H K
The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.
The Journal of pharmacology and experimental therapeutics 1954;112(3):356-63.
1954: LASAGNA L; BEECHER H K
The analgesic effectiveness of codeine and meperidine (demerol).
The Journal of pharmacology and experimental therapeutics 1954;112(3):306-11.
1954: LASAGNA L
Nalorphine (n-allylnormorphine); practical and theoretical considerations.
A.M.A. archives of internal medicine 1954;94(4):532-58.
1954: LASAGNA L; BEECHER H K
The optimal dose of morphine.
Journal of the American Medical Association 1954;156(3):230-4.
1954: LASAGNA L; VON FELSINGER J M
The volunteer subject in research.
Science (New York, N.Y.) 1954;120(3114):359-61.
1954: LASAGNA L; MOSTELLER F; VON FELSINGER J M; BEECHER H K
A study of the placebo response.
The American journal of medicine 1954;16(6):770-9.
1954: LASAGNA L
A comparison of hypnotic agents.
The Journal of pharmacology and experimental therapeutics 1954;111(1):9-20.
1953: BEECHER H K; KEATS A S; MOSTELLER F; LASAGNA L
The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo "reactors" and "non-reactors".
The Journal of pharmacology and experimental therapeutics 1953;109(4):393-400.
1953: VON FELSINGER J M; LASAGNA L; BEECHER H K
The persistence of mental impairment following a hypnotic dose of a barbiturate.
The Journal of pharmacology and experimental therapeutics 1953;109(3):284-91.
1952: BLANCHARD K C; DEARBORN E H; LASAGNA L C; BUHLE E L
The antidiuretic activity of some organic acids.
Bulletin of the Johns Hopkins Hospital 1952;91(5):330-40.
1952: DEARBORN E H; LASAGNA L
The antidiuretic action of epinephrine and norepinephrine.
The Journal of pharmacology and experimental therapeutics 1952;106(1):122-8.
1952: DEARBORN E H; LASAGNA L; MARSHALL E K
On the mechanism of the antidiuretic action of cinchoninic acid derivatives.
The Journal of pharmacology and experimental therapeutics 1952;106(1):103-21.
1952: LASAGNA L
Effects of potassium on the guinea pig after barbiturate administration.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1952;80(4):568-71.
1952: LASAGNA L; DEARBORN E H
Antidiuretic effects of physostigmine and atropine in the dog.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1952;80(3):430-1.
1952: LASAGNA L; ZUBROD C G
The relation of dosage schedule to the therapeutic efficacy of terramycin.
Bulletin of the Johns Hopkins Hospital 1952;90(5):372-81.
1951: LASAGNA L
Detection of norepinephrine in the parotid gland secretion of Bufo agua.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1951;78(3):876-8.
1951: FIERST S M; ROBINSON H M; LASAGNA L
Interstitial gastric emphysema following gastroscopy; its relation to the syndrome of pneumoperitoneum and generalized emphysema with no evident perforation.
Annals of internal medicine 1951;34(5):1202-12.
1949: PARISER S; LASAGNA L
Occlusion of the anterior spinal artery; a case report.
Journal of the Mount Sinai Hospital, New York 1949;16(2):128-31.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Louis Lasagna

Research Profile (preview)

Geographic Areas

Organizations

Procedures

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Occupations

Devices

Disorders

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Louis Lasagna (preview)

All Publications